Brainsway

BWAY · TEL

$11.25−$0.19 (−1.66%)TodayMarket closed ·
Prev close $11.44

About BWAY

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Employees
129
Headquarters
Jerusalem
Listed
Dec 24, 2006
Sector
Health Care
Industry
Health Care Equipment & Supplies

Leadership

Brainsway executives
NameTitleSince
Amiram Boehm——
Hadar Levy——
David Zacut—2006
Ido Marom——
Yiftach Roth—2006
Menachem Klein——
Eric Hirt——
Christopher Boyer——
Colleen Hanlon——
Moria Ben Soussan——
Aron Tendler——
Prof. Abraham Zangen——
Yosef Ben Shalom——
Avner Hagai——
Avner Lushi——
Eti Mitrany Rayten——
Karen Sarid——

Revenue by product and region

Fiscal year ended Dec 31, 2020: $22.06M total revenue

By region

  • USA [Member]$19.33M87.6%
  • Europes [Member]$1.85M8.4%
  • Others [Member]$730.00K3.3%
  • Israel [Member]$150.00K0.7%

Similar companies

Companies in the same industry as Brainsway

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.